NAPLEX • Pharmacy Management And Leadership

Technology And Informatics

Understanding how health information technology transforms medication safety, clinical decision-making, and pharmacy operations.

NAPLEX emblem with a medicine bottle, dosage calculator, and verification checks.
Inside this lesson 10 sections 5 questions 5 figures

SECTION 1

Historical Context & Motivation

The integration of technology into pharmacy practice did not happen overnight; it emerged from decades of patient safety crises, legislative mandates, and evolving informatics capabilities. Before the widespread adoption of health information technology (HIT), medication orders were handwritten, dispensing was entirely manual, and pharmacists had limited tools to intercept errors before drugs reached patients. The 1999 Institute of Medicine report To Err Is Human revealed that medical errors, including medication errors, killed an estimated 44,000 to 98,000 Americans per year, catalyzing a national movement toward systems-based safety solutions. This report, perhaps more than any other single event, shifted the healthcare conversation from blaming individual practitioners to redesigning the systems in which they worked.

1970s • Early Hospital Information Systems

Pioneering institutions such as the Regenstrief Institute and Brigham and Women's Hospital developed rudimentary computerized provider order entry (CPOE) systems, demonstrating that technology could reduce transcription errors and improve order legibility.

1999 • IOM Report — To Err Is Human

The landmark report quantified the staggering toll of medical errors, spurring federal investment in health IT as a systems-level safety intervention rather than an optional upgrade.

2004 • Office of the National Coordinator (ONC) Established

President George W. Bush created the ONC for Health Information Technology via executive order, setting a ten-year goal for interoperable electronic health records across the United States.

2009 • HITECH Act Enacted

The Health Information Technology for Economic and Clinical Health (HITECH) Act allocated approximately $27 billion in incentives for meaningful use of electronic health records, accelerating adoption nationwide.

2020s • AI, Interoperability, and Precision Pharmacy

Advanced clinical decision support, pharmacogenomic integration, machine learning–driven drug utilization review, and FHIR-based interoperability standards are reshaping pharmacy informatics toward personalized, data-driven care.

The central question driving pharmacy informatics has remained consistent throughout this evolution: how can information systems be designed to ensure the right patient receives the right drug, at the right dose, via the right route, at the right time — all while enabling pharmacists to exercise their clinical expertise more effectively? Each technological advance represents an attempt to close gaps in that process, and understanding this history equips future pharmacists to critically evaluate, implement, and optimize these systems in practice.

SECTION 2

Core Principles & Definitions

Pharmacy informatics sits at the intersection of pharmacy practice, information science, and computer technology. At its core, the discipline is concerned with acquiring, storing, analyzing, and disseminating medication-related data to optimize therapeutic outcomes and enhance patient safety. Several foundational concepts undergird this field, and a solid understanding of each is essential for NAPLEX preparation and for competent practice in any pharmacy setting.

1

Electronic Health Record (EHR)

A longitudinal digital record of a patient's health information generated across multiple encounters and care settings. EHRs contain medication lists, lab values, allergy data, and clinical notes that pharmacists use for medication therapy management.
2

Computerized Provider Order Entry (CPOE)

A system enabling prescribers to enter medication orders electronically, eliminating handwriting ambiguity and enabling real-time clinical decision support alerts for drug interactions, allergies, and dosing errors.
3

Clinical Decision Support Systems (CDSS)

Software that provides clinicians with patient-specific, evidence-based recommendations at the point of care. Examples include drug-drug interaction alerts, dose-range checking, and renal dosing recommendations.
4

Barcode Medication Administration (BCMA)

A technology requiring scanning of both the patient's identification band and the medication barcode before administration, verifying the five rights of medication safety at the bedside.
5

Interoperability & Health Information Exchange (HIE)

The ability of different information systems to exchange and meaningfully interpret shared data. Standards such as HL7 and FHIR enable seamless communication between pharmacy, hospital, and ambulatory systems.
✦

KEY TAKEAWAY

Think of pharmacy informatics as the nervous system of a healthcare organization. Just as the nervous system transmits signals between the brain and every organ to coordinate action, informatics infrastructure transmits medication-related data between prescribers, pharmacists, nurses, and patients to coordinate safe and effective therapy. Without a functioning nervous system, even the most skilled clinician is working in isolation — and isolation breeds errors.

SECTION 3

Visual Explanation — The Medication Use Process & Technology Touchpoints

The medication use process is a multistep workflow that spans prescribing, transcribing, dispensing, administering, and monitoring. At each stage, specific technologies serve as safety checkpoints. The diagram below maps each phase of the medication use process to the informatics tools that support it, illustrating how technology forms a layered safety net across the entire continuum.

Medication Use Process — Technology TouchpointsPRESCRIBINGCPOE + e-PrescribingTRANSCRIBINGEHR Interface EngineDISPENSINGRobots + AutomationADMINISTERINGBCMA + Smart PumpsMONITORINGADR Surveillance / PGxCLINICAL DECISION SUPPORT SYSTEM (CDSS) — Active Across All PhasesDrug-Drug Interactions • Allergy Alerts • Dose-Range Checking • Renal Dosing • Therapeutic DuplicationError Reduction by Technology TypeCPOE55%↓ prescribing errorsEliminates illegibilityEnables real-time alertsEnforces formulary rulesBates et al., 1998BCMA87%↓ administration errorsVerifies 5 rightsDocuments timestampsCreates audit trailPoon et al., 2010Smart Infusion Pumps73%↓ IV dosing errorsDrug library limitsHard/soft stop alertsDose error reduction SWRothschild et al., 2005
The top row traces the five phases of the medication use process from prescribing through monitoring, with the corresponding technology at each step. The amber CDSS bar runs beneath all phases, indicating that clinical decision support is active continuously. The lower panels quantify the error-reduction impact of three key technologies based on landmark studies.

As illustrated above, no single technology eliminates all medication errors; rather, each tool addresses a specific vulnerability within the medication use process. CPOE targets prescribing errors by eliminating illegible handwriting and embedding real-time alerts, while BCMA acts as the final safety gate before the medication reaches the patient. The CDSS layer is unique because it is not confined to a single phase — it operates continuously, cross-referencing patient data against evidence-based rules at every transition point. This layered defense-in-depth approach is the conceptual backbone of pharmacy informatics.

SECTION 4

How Health IT Systems Work — Architecture & Data Flow

Understanding the technical architecture of pharmacy information systems enables pharmacists to troubleshoot workflow inefficiencies, participate meaningfully in system implementation committees, and advocate for design improvements that enhance patient safety. Modern pharmacy informatics ecosystems operate on a layered architecture that integrates several interrelated modules.

E-Prescribing and the NCPDP SCRIPT Standard

Electronic prescribing (e-prescribing) uses the National Council for Prescription Drug Programs (NCPDP) SCRIPT standard to transmit prescriptions from the prescriber's EHR directly to the pharmacy's dispensing system. This standard encodes patient demographics, medication details (drug name, strength, dosage form, quantity, directions), prescriber identification (NPI number), and insurance eligibility data into structured electronic messages. For controlled substances, the DEA mandates the use of Electronic Prescriptions for Controlled Substances (EPCS), which requires two-factor authentication to verify prescriber identity and tamper-resistant digital signatures. EPCS significantly reduces prescription forgery and facilitates real-time monitoring via state Prescription Drug Monitoring Programs (PDMPs).

Clinical Decision Support — Alert Logic

CDSS engines operate through rule-based algorithms and, increasingly, through machine learning models. A typical rule-based alert fires when a prescribed medication triggers a condition stored in a knowledge base — for example, when warfarin is ordered for a patient whose current medication list includes fluconazole, generating a drug-drug interaction alert. The sensitivity of these alerts is a critical design parameter: overly sensitive systems produce alert fatigue, a well-documented phenomenon in which clinicians override or ignore warnings due to their excessive frequency. Studies have shown that override rates can reach 49–96% depending on the institution and alert type. Best practices include tiering alerts by severity (informational, soft stop, hard stop), tailoring rules to institutional formularies, and continuously reviewing override data to refine alert thresholds.

Automated Dispensing Cabinets (ADCs)

Automated dispensing cabinets (ADCs) such as Pyxis MedStation and Omnicell systems are decentralized, computer-controlled medication storage devices located in patient care areas. They interface with the pharmacy information system so that nurses can only access medications that have been verified by a pharmacist through a profile-based review. The profiled mode restricts access to medications specific to individual patients, while the override mode allows access to pre-designated urgent medications (e.g., epinephrine, naloxone) without pharmacist review. Override usage must be monitored and minimized, as bypassing pharmacist verification eliminates a critical safety check.

💡

NAPLEX Tip

Expect questions testing your understanding of when ADC overrides are appropriate versus when profiled mode should be enforced. Remember that ISMP recommends limiting override access to time-critical medications only, and that institutions should conduct quarterly audits of override activity to identify safety concerns.

SECTION 5

Detailed Breakdown — Key Pharmacy Technology Systems

Beyond the core technologies already discussed, several additional systems are integral to modern pharmacy operations and are frequently tested on the NAPLEX. The diagram below provides a hierarchical view of these systems organized by their primary function, followed by a detailed comparison table.

PHARMACY TECHNOLOGY ECOSYSTEMORDER PROCESSINGDISPENSING & STORAGESAFETY & MONITORINGCPOEElectronic order entry with CDSSe-Prescribing / EPCSNCPDP SCRIPT, 2FA for C-II–VPharmacy Benefit ManagerReal-time adjudication, prior authADCs (Pyxis / Omnicell)Profile & override modesRobotic DispensingCentral fill, unit-dose packagingInventory Management340B tracking, DSCSA complianceBCMABedside barcode verificationSmart Infusion PumpsDERS with hard/soft limitsPDMP IntegrationState database for C-II–V trackingDATA LAYER — EHR + HIE + Interoperability Standards (HL7 / FHIR)Connects all systems · Enables data sharing across institutions · Protected by HIPAA & HITECHAll systems ultimately feed into the electronic health record, creating a unified patient medication profile.
This hierarchical diagram organizes pharmacy technology into three functional domains: order processing (blue), dispensing and storage (violet), and safety and monitoring (green). All domains connect to a shared data layer (pink) built on EHR infrastructure and interoperability standards such as HL7 and FHIR.
TechnologyPrimary SettingKey FunctionRegulatory Driver
CPOEHospital / Health SystemElectronic order entry with embedded CDSSMeaningful Use / Promoting Interoperability
e-PrescribingAmbulatory / CommunityTransmits Rx from prescriber to pharmacyMedicare Part D mandate; state EPCS laws
ADCsHospital nursing unitsDecentralized, profile-controlled medication accessISMP guidelines, Joint Commission standards
BCMAHospital bedsideVerifies 5 rights before medication administrationJoint Commission NPSG
PDMPAll settings (state-operated)Tracks controlled substance dispensing historyState pharmacy practice acts; SUPPORT Act
TelepharmacyRural / underserved areasRemote pharmacist verification and counselingState board regulations (variable by state)

Summary of major pharmacy technology systems, their settings, functions, and regulatory drivers

SECTION 6

Worked Example — Evaluating a CDSS Alert Override Rate

Pharmacy informatics specialists routinely analyze alert data to optimize CDSS performance. The following scenario walks through a systematic evaluation of alert override rates, a metric that directly correlates with patient safety and system usability.

Analyzing Drug-Drug Interaction Alert Override Rates

  1. 1

    Step 1 — Identify the Data

    A hospital pharmacy informatics team reviews CDSS data from Q3. The system generated 12,400 drug-drug interaction (DDI) alerts during this period. Of these, prescribers overrode 9,672 alerts. The team needs to calculate the override rate, compare it to benchmarks, and propose interventions.
  2. 2

    Step 2 — Calculate the Override Rate

    Override Rate = (Number of Overridden Alerts ÷ Total Alerts Generated) × 100. Substituting: (9,672 ÷ 12,400) × 100 = 78.0%. This means nearly four out of every five DDI alerts were dismissed by prescribers.
    Override Rate = 78.0%
  3. 3

    Step 3 — Compare to Benchmarks

    Published literature suggests that DDI alert override rates in many institutions range from 49% to 96%. While 78% falls within this range, it is still indicative of significant alert fatigue. The ISMP and ASHP recommend that institutions aim to reduce clinically inappropriate overrides by focusing alert refinement on high-severity interactions.
  4. 4

    Step 4 — Categorize Overrides by Severity

    The team stratifies the 9,672 overrides: 7,450 (77.0%) involved low-severity interactions (e.g., simvastatin + amlodipine), 1,740 (18.0%) involved moderate-severity interactions, and 482 (5.0%) involved high-severity interactions (e.g., methotrexate + trimethoprim). The 482 high-severity overrides represent the most concerning safety signal.
    482 high-severity overrides — priority for intervention
  5. 5

    Step 5 — Recommend Interventions

    Based on this analysis, the team recommends: (1) Suppress or convert low-severity DDI alerts to passive informational messages that do not require acknowledgment, eliminating approximately 7,450 interruptive alerts per quarter. (2) Retain moderate-severity alerts as soft stops with required reason-for-override documentation. (3) Escalate high-severity alerts to hard stops that require pharmacist verification before the order can proceed. (4) Implement a quarterly review cycle to reassess alert thresholds based on updated evidence and override patterns.
    Projected reduction: ~60% fewer interruptive alerts with preserved safety for high-risk interactions

SECTION 7

Strengths, Limitations, and Challenges of Pharmacy Technology

While pharmacy technology has demonstrably improved medication safety and operational efficiency, it is not without limitations. A nuanced understanding of both the benefits and the risks associated with these systems is essential for pharmacists who serve as end users, system administrators, and patient safety advocates.

DimensionStrengthsLimitations / Risks
Patient SafetyReduces prescribing, dispensing, and administration errors through layered safety checks (CPOE, CDSS, BCMA)Alert fatigue may cause clinicians to override critical warnings; new error types (e.g., wrong-patient selection in EHR) can emerge
EfficiencyAutomates routine tasks (counting, labeling, adjudication), freeing pharmacists for clinical activitiesSystem downtime disrupts workflow; workaround procedures during outages may lack safety controls
Data QualityStructured data enables drug utilization review, outcomes research, and population health analyticsGarbage in, garbage out — incomplete or inaccurate data entry undermines CDSS effectiveness and research validity
InteroperabilityHL7/FHIR standards enable cross-institutional data sharing; HIEs improve care transitionsProprietary EHR platforms may resist true interoperability; data silos persist across many health systems
Privacy & SecurityHIPAA and HITECH establish robust protections; audit trails enable accountabilityCybersecurity threats (ransomware, phishing) can compromise patient data and disable critical systems
CostLong-term ROI through reduced ADEs, shorter lengths of stay, and improved formulary adherenceHigh upfront capital costs; ongoing maintenance, training, and customization expenses

Strengths and limitations of pharmacy technology across key dimensions

✦

KEY TAKEAWAY

Technology is a tool, not a panacea. Consider the analogy of autopilot in aviation: it dramatically reduces pilot error during routine operations, but it can introduce new failure modes (automation complacency, mode confusion) that require trained humans to detect and correct. Similarly, pharmacy informatics systems reduce predictable errors while occasionally introducing novel ones. The pharmacist's role is evolving from being the sole error-catching mechanism to being the expert who designs, monitors, and refines the technological systems that catch errors at scale.

SECTION 8

Connection to Advanced Topics — Emerging Pharmacy Informatics

The landscape of pharmacy informatics is evolving rapidly, driven by advances in artificial intelligence, genomics, and regulatory frameworks. Future pharmacists will be expected not only to use these technologies but to evaluate their clinical validity, advocate for their responsible deployment, and lead implementation efforts within their organizations.

Current StandardEmerging / Future DirectionImplication for Pharmacy
Rule-based CDSS (if-then logic)AI/ML-driven predictive CDSSAlgorithms predict adverse drug events before they occur by analyzing patterns in patient data; pharmacists must evaluate algorithm validity and bias
Population-based dosing guidelinesPharmacogenomic CDS integrationEHR-embedded pharmacogenomic alerts (e.g., CYP2D6 poor metabolizer + codeine → recommend alternative); pharmacists interpret and act on genotype-guided recommendations
HL7 v2 messagingFHIR-based interoperabilityRESTful APIs enable third-party apps to access EHR data securely; opens ecosystem for pharmacy-specific tools and patient-facing medication management apps
Paper-based serialization trackingDSCSA full traceability (2024+)The Drug Supply Chain Security Act mandates unit-level serialization and electronic, interoperable tracing from manufacturer to dispenser, combating counterfeit drugs
In-person counseling onlyTelepharmacy and digital healthRemote medication therapy management, virtual verification, and app-based adherence monitoring expand pharmacist reach to underserved populations

Current pharmacy informatics standards compared with emerging directions

As these technologies mature, the pharmacist's informatics competency will become as fundamental as pharmacokinetic knowledge. The American Society of Health-System Pharmacists (ASHP) has identified informatics as a core competency for all residency-trained pharmacists, and the NAPLEX increasingly reflects this expectation. Students should anticipate questions that test not only knowledge of specific technologies but also the ability to critically evaluate system design, identify workflow vulnerabilities, and propose evidence-based improvements.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A pharmacist notices that prescribers on the medical-surgical unit are overriding more than 90% of drug-drug interaction alerts in the CPOE system. What is the most likely cause of this behavior, and what is the primary patient safety concern it creates?
Show answer
The most likely cause is alert fatigue, a well-documented phenomenon that occurs when clinicians are exposed to an excessive volume of low-value or clinically insignificant alerts, leading them to habitually dismiss warnings without careful review. The primary safety concern is that among the overridden alerts, some may represent genuinely dangerous interactions that could result in adverse drug events. When override rates approach or exceed 90%, the CDSS effectively loses its protective function, as clinicians develop a pattern of dismissing alerts reflexively rather than evaluating each one on its clinical merits. Addressing this requires tiering alerts by severity and suppressing or converting low-value alerts to non-interruptive notifications.

Question 2: BASIC CALCULATION

A hospital's automated dispensing cabinet system logged 340 medication access events in one 24-hour period. Of these, 28 were overrides that bypassed pharmacist profile review. Calculate the override rate and determine whether it falls within ISMP's recommended threshold of less than 5% of total accesses.
Show answer
Override Rate = (28 ÷ 340) × 100 = 8.2%. This exceeds the ISMP-recommended threshold of less than 5% of total ADC accesses. An 8.2% override rate suggests that medications are being accessed without pharmacist verification more frequently than is considered safe. The informatics team should audit the override log to determine which medications are being overridden, whether the overrides occurred during off-hours when pharmacist staffing is reduced, and whether the override list includes medications that should not qualify for emergent access. Interventions might include expanding pharmacist coverage hours, restricting the override formulary to truly time-critical medications (e.g., naloxone, epinephrine, first-dose antibiotics for sepsis), and implementing hard stops for high-risk medications.

Question 3: INTERMEDIATE

A community pharmacy is implementing e-prescribing for controlled substances (EPCS). The pharmacy manager asks you to explain the authentication requirements that differentiate EPCS from standard e-prescribing. What are the key regulatory requirements, and why do they exist?
Show answer
EPCS requires two-factor authentication (2FA) as mandated by the DEA. The prescriber must present two of the following three credential types: (1) something they know (password or PIN), (2) something they have (a hard token, cryptographic device, or registered mobile device), or (3) something they are (biometric identifier such as fingerprint). Standard e-prescribing for non-controlled substances requires only routine login credentials. The heightened authentication for EPCS exists because controlled substances carry a higher risk of diversion, fraud, and abuse. Two-factor authentication ensures that the identity of the prescriber is verified at the time of signing, making it exceedingly difficult for unauthorized individuals to generate fraudulent prescriptions. Additionally, EPCS creates a tamper-evident audit trail that supports PDMP monitoring and DEA enforcement. Many states now mandate EPCS for all controlled substance prescriptions, superseding the previous allowance for handwritten prescriptions.

Question 4: APPLIED

You are a pharmacy informaticist at a 400-bed hospital transitioning from paper-based medication administration records to barcode medication administration (BCMA). During the first month of go-live, nursing staff report that the BCMA system rejects scans for approximately 15% of doses because the barcode on the unit-dose package does not match the EHR order. Identify at least three root causes and propose a corrective action plan.
Show answer
Three likely root causes include: (1) Product catalog mismatches — the EHR medication dictionary may map to a different National Drug Code (NDC) than the barcode printed on the product actually in inventory, particularly when the purchasing department switches generic manufacturers without notifying the informatics team. (2) Repackaging errors — the in-house repackaging unit may have applied incorrect barcodes to unit-dose packages, or the repackaging software may not be synchronized with the pharmacy information system. (3) Order entry discrepancies — the prescriber may have selected a different dosage form or strength in CPOE than what the pharmacy dispensed, creating a legitimate mismatch that the BCMA system correctly flags. The corrective action plan should include: convening a multidisciplinary team (pharmacy, nursing, informatics, purchasing) for daily huddles during the first 90 days; conducting a line-by-line audit of NDC-to-formulary mappings; implementing a change management protocol requiring purchasing to notify the informatics team before any manufacturer or NDC switches; and establishing a rapid-response process for nurses to report scan failures so they can be resolved in real time rather than leading to workarounds that bypass the safety system.

Question 5: CRITICAL THINKING

A health system is evaluating whether to integrate an artificial intelligence–based clinical decision support tool that uses machine learning to predict patients at high risk for opioid-related adverse events. The algorithm was trained on data from a large urban academic medical center. Discuss at least three critical considerations the pharmacy informatics committee should address before adopting this tool, including potential ethical and clinical concerns.
Show answer
The committee should address the following considerations: (1) External validity and generalizability — an algorithm trained on data from a single urban academic center may not perform accurately when applied to a different patient population. Differences in demographics, disease prevalence, prescribing patterns, and social determinants of health between the training population and the implementing institution could reduce predictive accuracy or introduce systematic bias. The committee should request validation studies performed on diverse populations and consider conducting local validation before deployment. (2) Algorithmic bias and equity — machine learning models can perpetuate or amplify existing healthcare disparities. If the training data reflected racial or socioeconomic biases in pain management or opioid prescribing, the model might disproportionately flag patients from certain demographic groups, potentially leading to under-treatment of pain in already disadvantaged populations. An equity impact assessment should be conducted. (3) Transparency and explainability — clinicians need to understand why the algorithm flags a particular patient to make informed clinical decisions. Black-box models that provide risk scores without explanations are difficult to integrate into clinical workflows and may reduce clinician trust and adoption. The committee should evaluate whether the tool provides interpretable output. (4) Workflow integration and alert design — even a highly accurate model will fail if it generates excessive or poorly timed alerts. The committee must determine where in the workflow the alert appears, who receives it (prescriber, pharmacist, or both), and what action options are provided. (5) Regulatory and liability considerations — the committee should clarify whether the tool is FDA-cleared as a clinical decision support device, what documentation is required if a clinician overrides an AI recommendation, and how liability is allocated if the algorithm fails to identify a patient who subsequently experiences an adverse event.

SUMMARY

Summary — Technology and Informatics in Pharmacy

Summary

Pharmacy informatics encompasses the systems and processes that manage medication-related data across the entire medication use process. Key technologies include computerized provider order entry (CPOE) for eliminating prescribing errors, clinical decision support systems (CDSS) that provide real-time, evidence-based alerts across all workflow phases, automated dispensing cabinets (ADCs) for secure, profile-controlled medication access, and barcode medication administration (BCMA) for bedside verification of the five rights. E-prescribing and EPCS ensure secure, standardized prescription transmission, while Prescription Drug Monitoring Programs (PDMPs) track controlled substance dispensing to combat diversion.

Critical concepts for the NAPLEX include understanding alert fatigue and its mitigation through severity-tiered alert design, the distinction between profiled versus override ADC access, the regulatory drivers behind meaningful use and the HITECH Act, and interoperability standards (HL7, FHIR) that enable health information exchange. Emerging trends such as AI-driven predictive analytics, pharmacogenomic CDS, and telepharmacy are expanding the pharmacist's role as an informatics leader. Remember: technology provides the safety net, but the pharmacist provides the clinical judgment to ensure it functions as intended.

Varsity Tutors • NAPLEX • Technology And Informatics